Following Dura Pharmaceuticals, Inc., v. Broude, 544 U.S. 356 (2005), securities law plaintiffs can no longer simply plead “fraud on the market” to link the claimed fraud to the economic injury. While such an allegation continues to suffice as to …

LIABILITY IN SECURITIES FRAUD ACTIONS: Part XX: Theories of Proof Under Dura. Read More »

Hedge Funds — Last week, the SEC continued to focus on hedge funds and insider trading, while option backdating, another current enforcement favorite, apparently continued to spread.  As we described last week (see here), the agency brought another case involving PIPE …

The Week In Review (September 17-21, 2007): The SEC Continues to Focus on Favorite Targets While The GAO Targets the SEC Read More »